Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Posted: September 15, 2024 at 2:45 am

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP

Read more:
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Related Posts